US proposal to halve biosimilar development costs for India's Biocon, top exec says India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback